METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to control Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether adding a new drug called SX-682 to the existing drug apalutamide can help control metastatic castration-resistant prostate cancer (mCRPC) in men. The trial involves 78 participants and will check for safety, the right dose, and signs that the cancer is sh…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called TmPSMA-02, which uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack prostate cancer cells. The goal is to find a safe dose and see if it can shrink tumors or slow the disease in…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 26, 2026 07:50 UTC
-
Could customizing radiation doses improve prostate cancer treatment?
Disease control Recruiting nowThis study tests whether giving a personalized dose of a radioactive drug (177Lu-PSMA-617) based on kidney radiation exposure is safer and allows higher doses than the standard fixed dose. About 60 men with advanced prostate cancer that no longer responds to hormone therapy will …
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Jean-Mathieu Beauregard • Aim: Disease control
Last updated May 22, 2026 14:03 UTC